Exagen (XGN) Free Cash Flow (2018 - 2026)

Exagen has reported Free Cash Flow for 9 years, with the latest figure at -$10.6 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 1.29% year-over-year to -$10.6 million; the trailing twelve-month figure through Mar 2026 stood at -$14.1 million (up 8.57% YoY), and the FY2025 full-year result was -$14.3 million, down 3.42% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$10.6 million, down from -$3.6 million in the prior quarter.
• The five-year high for Free Cash Flow was $9.0 million in Q4 2023, with the low at -$13.1 million in Q2 2022.
• Historically, Free Cash Flow has averaged -$5.3 million across 5 years, with a median of -$6.1 million in 2022.
• Annual changes were most pronounced in 2023 — Free Cash Flow surged 246.66% — and 2025, when it plunged 1776.04%.
• Exagen's Free Cash Flow stood at -$6.1 million in 2022, then surged by 246.66% to $9.0 million in 2023, then tumbled by 97.59% to $217000.0 in 2024, then sank by 1776.04% to -$3.6 million in 2025, then plunged by 192.69% to -$10.6 million in 2026.
• The last three Free Cash Flow figures came in at -$10.6 million (Q1 2026), -$3.6 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.